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Abstract:
Ocular medulloepitheliomas, adenomas and adenocarcinomas share a common phenotype
and originate from the cells of the ciliary epithelium.  This can make it very difficult to
differentiate between these tumors histopathologically.  Therefore, this study focused on
identifying a combination of immunological markers that might be used in the diagnosis of these
tumors. These markers included AE1/AE3, CK7, CK20, and telomerase reverse transcriptase
(TERT).
Routine immunohistochemical staining was performed on twenty-one whole globes
diagnosed with one of these tumors. The tumors that immunostained for TERT showed
increasing immunoreactivity as the tumor types increased in aggressiveness. None of the tumor
types were immunopositive for CK7.  CK20 immunostaining was found in the adenomas but not
in the adenocarcinomas or medulloepitheiomas. AE1/AE3 expression was present more
consistently in the adenocarcinomas and less frequently in the adenomas. There was no
AE1/AE3 expression in the medulloepitheliomas confirming their mesenchymal origin.
Furthermore, CK20 and TERT show inverse expression patterns, i.e., TERT increases in
expression and CK20 decreases in expression with increasing aggressiveness. These results may
be important diagnostic and prognostic indicators for these tumors. (195 words)
Key Words:
Immunohistochemistry, medulloepithelioma, adenocarcinoma, adenoma, telomerase, telomerase
reverse transcriptase (TERT), CK7, CK20, AE1/AE3
Introduction:
Medulloepithelioma is an extremely rare congenital, unilateral ocular tumor that arises
mainly from the undifferentiated nonpigmented epithelium of the ciliary body (optic cup).1,15,20
The tumor originates from portions of the embryonic medullary epithelium of the forebrain and
optic vesicles (neuroectoderm); as such, these tumors have the ability to differentiate into various
cell types.15 There are two classifications of this tumor:  teratoid and non-teratoid
medulloepitheliomas.  Teratoid medulloepitheliomas contain heteroplastic tissues not normally
seen in the mammalian eye, such as cartilage, muscle fibers, and neuronal tissue. Nonteratoid
and teratoid medulloepitheliomas are unlike retinoblastoma in their pluripotential properties.46
Medulloepitheliomas arise most frequently in young children but they have also been described
in other species, including dogs, cats, horses, cockatiels, a goldfish, and a llama.1,15,5,10,17,22-
25,37,42,45
It is often difficult to differentiate medulloepitheliomas from other tumors that arise from
the ciliary epithelium, i.e. adenomas and adenocarcinomas. Therefore, this study focused on
characterizing these tumors using a variety of antibodies.  These endeavors are especially
important for neoplasms of veterinary species where information is more limited.  This study
also sought to investigate the expression of TERT, the catalytic subunit of telomerase.
Telomerase is a ribonucleoprotein complex that is present in the majority of tumors to allow
unlimited replicative abilities by maintaining the telomeres. Telomerase activity has been used in
tumors of humans and dogs to predict prognosis and aggressiveness of the tumors.3,14,16,38,43
TERT was used in this study as an indirect marker of telomerase activity.16
Materials and Methods:
• Tissue Preparation
Twenty seven samples were obtained from the Ophthalmic Pathology Service from The
School of Veterinary Medicine, University of Wisconsin.  There were fourteen adenoma
samples, categorized as either non-invasive (n=7) or invasive (n=7).  Seven samples were
classified as adenocarcinomas, and six specimens were medulloepitheliomas.  All samples were
canine ocular globes (Table 1), which were fixed in 10% buffered neutral formalin, paraffin
embedded, and evaluated histologically by Dr. Dubielzig, our collaborative veterinary
ophthalmic pathologist. Sections were cut at 5µm onto charged slides (Probe-On Plus, Fisher
Scientific, Pittsburg, PA) for immunohistochemical staining.
• Antibodies
Immunohistochemical staining was performed using antibodies against telomerase
reverse transcriptase (TERT, Santa Cruz, 1:350), CK7 (CK 7, Super Sensitive Ready-to-Use
Antibody, BioGenex, San Ramon, CA), CK20 (CK 20, Super Sensitive Ready-to-Use Antibody,
BioGenex, San Ramon, CA), CKAE1 and CKAE3 (DAKO Corp., Carpinteria, CA, 1:50).
DAKO Antibody Diluent with Background Reducing Components (DAKO Corp., Carpinteria,
CA) was used for antibodies requiring dilution.
TERT (Santa Cruz Biotechnology, Inc.,) is an affinity-purified goat-anti-rabbit polyclonal
antibody raised against a peptide mapping at the carboxy terminus of telomerase reverse
transcriptase of human origin.  TERT was used at a 1:350 dilution. CK20 (Super Sensitive
Ready-to-Use Antibody, BioGenex, San Ramon, CA) is a mouse monoclonal antibody diluted in
phosphate buffered saline, pH 7.6 containing 1% BSA and 0.09% sodium azide. CK7 (Super
Sensitive Ready-to-Use Antibody, BioGenex, San Ramon, CA) is a mouse monoclonal antibody
from ascites and diluted in phosphate-buffered saline, pH 7.6 containing 1% BSA and 0.09%
sodium azide.  Anti-AE1/AE3 is a cocktail of two monoclonal antibodies for cytokeratins; and it
is used to identify cells of simple and stratified epithelial origin.41  Staining for this antibody was
performed by The Ohio State University Immunohistochemical Staining Laboratory.
• Immunohistochemical staining
The avidin-biotin peroxidase complex (ABC) method was used with all antibodies.8
Samples were deparaffinized in xylene and rehydrated in decreasing concentrations of alcohols
followed by washing in 1X phosphate-buffered saline (PBS).  Slides were incubated for 10
minutes at 37°C with DAKO Ready-to-Use Peroxidase Blocking Reagent (DAKO Corp.,
Carpinteria, CA) to block endogenous peroxidase activity.  Slides were then incubated with
DAKO Ready-to-Use Protein Block Serum (Dako Corp., Carpinteria, CA) for 10 minutes at
37°C to block nonspecific protein binding.  Samples were incubated with the appropriate
primary antibody overnight at 4°C, washed, then incubated in secondary antibody (mouse or
rabbit Biogenex Super Sensitive Link, Biotinylated Immunoglobulins, Biogenex, San Ramon,
CA) for 45 minutes at 37°C.  Slides were labeled with Biogenex Super Sensitive Label,
Peroxidase-Conjugated Streptavidin for 30 minutes at 37°C.  Immunostaining was then
visualized with either 3,3¢-diaminobenzidine tetrahydrochloride (DAB, DAKO Corp.,
Carpinteria, CA), prepared according to instructions for 3 minutes at room temperature in the
dark or Vector NovaRED (Vector Laboratories, Burlingame, CA) for 5 minutes at room
temperature.  Following washes, slides were counterstained with hematoxylin for 3 minutes at
room temperature, dehydrated and permanently mounted.  For negative controls, primary
antibodies were omitted and samples were incubated in DAKO Antibody Diluent with
Background Reducing Components (DAKO Corp., Carpinteria, CA).
One additional step, antigen retrieval, was included following the rehydration which
unmasked hidden epitopes when staining with TERT, CK20 and CK7. TERT was treated with
DAKO Target Retrieval Solution (DAKO Corp., Carpinteria, CA) for 20 minutes in a steam bath
then 20 minutes at room temperature. CK20 was pretreated with Protease (Invitrogen, Carlsbad,
CA) for 10 minutes at room temperature. CK7 was pretreated with Pepsin (Biogenex, San
Ramon, CA) for 5 minutes at 37°C.
A pathologist blinded to the details of the study (Dr. Donna Kusewitt) interpreted the
immunohistochemistry results.  Results were rated as positive (the majority of tumor cells were
positive), negative (all of the tumor cells were negative), or +/- which indicated that some tumors
cells were positive while others were negative. These ratings were assigned a number: majority
of cell were positive (2), few positive cells (1), or negative (0); and statistical analysis was
performed using a one way ANOVA with Tukey’s test of comparable means (Prism 4 software).
Results:
Positive telomerase staining was seen as red since NovaRED was used as the chromogen.
CK20, CK7 and AE1/AE3 had brown positive staining because DAB was used as the
chromogen. The immunohistochemical staining results for each tumor sample are listed in Table
2.
Non-invasive adenomas were found to be significantly immunoreactive  (p<0.001) for
CK20 when compared to invasive adenomas, adenocarcinomas, and medulloepitheliomas
(Figures 1-5 B). Non-invasive adenomas had significantly less immunostaining for TERT than
invasive adenomas, adenocarcinomas, and medulloepitheliomas. There was no significant
difference in immunostaining for AE1/AE3 in adenocarcinomas when compared to non-invasive
and invasive adenomas, but medulloepitheliomas were immunonegative for AE1/AE3 (Figures
1-4 C and 5C). All tumors were negative for CK7 (Figures 1-4 D).
The invasive adenomas expressed significantly less CK20 than the noninvasive
adenomas. They expressed significantly more TERT than the noninvasive adenomas. There was
no significant difference in expression of AE1/AE3 between invasive adenomas, noninvasive
adenomas and adenocarcinomas. None of the invasive adenomas expressed CK7 (Figure 2).
Adenocarcinomas did not express CK7 or CK20, but TERT and AE1/AE2 were
expressed in this tumor type (Figure 3).  Medulloepitheliomas did not express CK20, CK7 or
AE1/AE3, but this tumor type expressed TERT (Figure 4).
Immunoreactivity for TERT was seen in all four tumor-types with increasing
immunoreactivity as the tumors increased in aggressiveness (Figures 1-5 A).  The non-invasive
adenomas showed less immunoreactivity with the anti-TERT antibody than the other tumors
(mean=0.4286).  The invasive adenomas (mean=1.822), adenocarcinomas (mean=2.000), and
medulloepitheliomas (mean=2.000) were all strongly immunopositive with anti-TERT antibody.
The invasive adenomas, adenocarcinomas, and medulloepitheliomas had significantly more
TERT immunoreactivity than the non-invasive adenomas (p<0.001).
CK20 was expressed with the non-invasive adenomas and some of the invasive adenomas
(Figures 1 and 2 B).  CK20 was not expressed in the adenocarcinomas or medulloepitheliomas
(Figures 3 and 4 B).  CK7 was not reactive with any of the tumor-types (Figures 1-4 D).
AE1/AE3 were expressed infrequently in the adenomas and more consistently in the
adenocarcinomas (Figures 1-3 C).  AE1 and AE3 were not present in any medulloepitheliomas
(Figure 4).
• Statistical Significance
The data for tumor immunoreactivity for TERT showed a significant difference between
the non-invasive adenomas and the other three tumor types, the invasive adenomas,
adenocarcinomas and medulloepitheliomas (Figure 5 A and Table 3).  The p-values for these
comparisons were all less than 0.05.  The invasive adenomas, adenocarcinomas, and
medulloepitheliomas expressed more TERT than the non-invasive adenomas.
CK20 immunoreactivity was significantly higher in the non-invasive adenomas when
compared to the invasive adenomas, adenocarcinomas, and medulloepitheliomas (Figure 5 B
and Table 3).  The p-values for these comparisons were all less than 0.05. All tumors received a
score of 0 for immunoreactivity with CK7, therefore, statistical analysis was not performed on
these.
AE1/AE3 immunoreactivity was significantly higher in the adenocarcinomas than the
adenomas (Figure 5 C and Table 3). None of the medulloepitheliomas were positive for
AE1/AE3.
Discussion:
Medulloepitheliomas are usually locally aggressive and may infiltrate the area around the
lens.20 The tumors can be malignant or benign, and histologically, demonstrate poorly
differentiated neuroectodermal tissue that may resemble embryonic retina.46 Large Homer-
Wright and Flexner-Wintersteiner rosettes can also be observed.15,20,26 Numerous studies have
characterized these tumors using immunohistochemical staining.5,18,20 The neuroepithelial cells
are positive for neuron-specific enolase, vimentin, S-100 protein, synaptophysin, and glial
fibrillary acidic protein (GFAP).20,26,46 The neuroblastic cells are usually positive for neuron-
specific enolase and synaptophysin.46 Medulloepitheliomas originate from the ciliary epithelium
as do adenomas and adenocarcinomas making their diagnostic differentiation difficult. Though
metastasis is atypical for all three tumor types, it is still important to properly diagnose them
especially if they are identified early and excised without enucleation of the globe.
Adenocarcinomas occur more frequently in adult humans and show a wide range of
severity, from differentiated malignant neoplasms to poorly differentiated pleomorphic tumors.
Adenocarcinomas histopathologically show increased necrosis and mitosis, as well as
pleomorphism when compared to adenomas which only show moderate pleomorphism and few
mitoses; adenomas are usually benign.26 Adenomas express vimentin, S-100 protein, and low-
molecular weight cytokeratins.46 The tumors can show a variety of histological patterning
including tubular, solid, and tubular/solid combination patterns and the cells are often heavily
pigmented and vacuolated. Adenocarcinomas also show these patterning types and they have
been shown to express vimentin, epithelial basement membrane antigen, and S-100 protein.46
 Telomerase is a ribonucleoprotein complex that maintains telomeres, the ends of
chromosomes, in most neoplastic cells, germline cells, and some stem cells.19 Expression of
telomerase activity allows cellular immortality by preventing the shortening of telomeres.4,36 The
functional telomerase complex is comprised of two main components, the catalytic subunit,
TERT, and the RNA subunit, TR. TR is expressed in most cells including those that lack
telomerase activity12 but TERT is the limiting factor in which expression correlates with
telomerase activity.9,2,31,44 TERT also has anti-apoptotic functions independent of TR.13,27,28,47
The combination of TERT’s anti-apoptotic functions and its function as the catalytic subunit of
the telomerase holoenzyme complex are synergistic in their effects on the immortality of
neoplastic and other telomerase-positive cells. Since telomerase activity can only be evaluated in
fresh tissues by the telomeric repeat amplification protocol,19 an indirect method of evaluating
telomerase activity was used, that is, immunohistochemical staining for the TERT protein.21
Numerous tumors, including neuroblastomas, malignant brain tumors, and colon, breast and
ovarian carcinomas, as well as others6,7,16,32,33,38,39, have a strong correlation between TERT
mRNA and/or protein expression and telomerase activity. In addition, expression of TERT by
immunohistochemical evaluation has correlated strongly with aggressiveness and metastatic
potential.16,32 The tumors evaluated in this study are not typically highly metastatic but they can
be locally aggressive; therefore, TERT and the other markers were used in an effort to create a
set of prognostic and diagnostic criteria for their behavior.
TERT expression was seen in three of the four tumor-types with increasing
immunoreactivity as the tumor types increased in aggressiveness.  The non-invasive adenomas
showed little to no expression of TERT supporting their benign nature. This was statistically
significant when compared to the other tumors evaluated (p<0.0001); almost all of the invasive
adenomas (85.7%) expressed TERT and all of the adenocarcinomas and medulloepitheliomas
had strong immunoreactivity for TERT, indicating that their behavior was more aggressive when
compared to the non-invasive adenomas. These findings support the premise that telomerase
activity is increased in tumor cells to allow uncontrolled proliferation and more aggresive
behavior.
Cytokeratins are important components of the cytoskeleton found in epithelial cells and
tumors of epithelial origin.11,26 There are twenty different cytokeratins and their expression is
tissue-specific, thus cytokeratin typing can be important in analyzing tumors and deducing their
origin.11,26 CK7 is an intermediate filament protein that has been found in the glandular
epithelium of many organs including lung, cervix, ovary, and breast, as well as urinary bladder
transitional epithelium, bile ducts, collecting ducts of the kidney, and mesothelium.34 CK7 is
absent in the gastrointestinal epithelium, hepatocytes, proximal and distal tubules of the kidney,
prostate, thymus, Merkel cells, and myoepithelium.34 The protein is also absent in
adenocarcinomas of the gastrointestinal epithelium34,35 as well as all of the tumors evaluated in
this study.
CK20 is an intermediate filament protein usually expressed in adenocarcinomas
originating from the epithelium of the intestine, colon, ovary, urothelium, and Merkel cells.29,30
CK20 has also been found in breast, lung, and endometrial carcinomas, but not in the non-
neoplastic epithelial cells of these organs.11 This study found that CK20 was expressed in both
non-invasive and invasive adenomas but not in adenocarcinomas. This lends support to the idea
of the protein being expressed in well-differentiated cells but not in cells of the same type as they
become more neoplastic and aggressive. Since medulloepitheliomas are of mesenchymal origin,
they were not expected to and did not express CK20.
Anti-cytokeratins AE1 and AE3 recognize the keratin subfamily; they can be used to
differentiate between epithelial and non-epithelial neoplasms.  AE1 specifically recognizes the
keratins in the acidic subfamily and AE3 recognizes the keratins in the basic subfamily. AE3 has
been found in both nonpigmented ciliary epithelial tumor cells and non-neoplastic cells, whereas
AE1 was only expressed in tumor cells.40 This study found the adenocarcinomas to have the
highest expression of AE1/AE3 with less expression in the adenomas. This suggests that
AE1/AE3 expression increases as the tumors become more aggressive. Since
medulloepitheliomas are of mesenchymal origin, they were not expected to and did not express
AE1/AE3.
In this study, cytokeratins AE1 and AE3 were expressed more consistently in the
adenocarcinomas and variably in the non-invasive and invasive adenomas. This is in contrast to
CK20, which was positive in most of the non-invasive adenomas but decreased in expression as
tumors increased in aggressiveness. The non-invasive adenomas were the only tumor type found
to be immunoreactive with CK20 and showed little or no reactivity for TERT. This would further
support TERT and telomerase activity’s role in neoplastic progression.  CK20 expression
decreased as the ciliary body tumors became more aggressive. AE1 and AE3 were not present in
any medulloepitheliomas confirming that they are not originating from ectodermal tissue;
previous studies have shown them to express vimentin, confirming their mesenchymal origin.5,15
The AE1/AE3 results confirm that, unlike medulloepitheliomas, adenomas and adenocarcinomas
are of ectodermal origin. CK7 was not reactive with any of the tumor-types.
AE1/AE3 keratins and cytokeratins 7 and 20 have been used to characterize human
pleomorphic adenocarcinomas of the ciliary epithelium. AE1/AE3 immunostaining was found in
most adenocarcinomas, similar to our study; CK7 immunostaining was found in almost half of
the tumors; and CK20 was not expressed in any tumor.26 This is opposite to the findings of this
study and may be species specific or perhaps characteristic to the pleomorphic nature of  the
human tumor.
The results of this study demonstrate some distinct immunostaining patterns for the
tumors evaluated (Table 3).  The results add new information to the current available knowledge
regarding these tumor types.  Of special interest is the inverse expression of telomerase and
CK20.  These results may be important in predicting the behavior of these tumors and may be
useful for the diagnosis and differentiation of adenomas, adenocarcinomas, and
medulloepitheliomas.
Acknowledgements:
The authors would like to sincerely thank Heather Chandler and staff of the Laboratory of
Molecular and Comparative Ophthalmology for the guidance, assistance and support that was
provided.
References:
1  al-Torbak A, Abboud EB, al-Sharif A, el-Okda MO: Medulloepithelioma of the ciliary body.
Indian J Ophthalmol 50: 138-140, 2002
2  Beattie TL, Zhou W, Robinson MO, Harrington L: Reconstitution of human telomerase
activity in vitro. Current Biology 8: 177-180, 1998
3  Biller BJ, Kitchell BE, Cadile CD: Evaluation of an assay for detecting telomerase activity in
neoplastic tissues of dogs. Am J Vet Res 59: 1526-1529, 1998
4  Blasco MA, Gasser,S.M., Lingner,J.: Telomeres and telomerase. Genes and Development 13:
2353-2359, 1999
5  Bras ID, Metzler AG, Kusewitt DF, Colitz CMH, Wilkie DA: Immunohistochemical
characterization of a malignant intraocular teratoid medulloepithelioma in a cockatiel.
Vet Ophthalmol 8: 59-65, 2005
6  Braunstein I, Cohen-Barak O, Shachaf C, al e: Human telomerase reverse transcriptase
promoter regulation in normal and malignant human ovarian epithelial cells. Cancer Res
61: 5529-5536, 2001
7  Cabuy E, de Ridder L: Telomerase activity and expression of telomerase reverse transcriptase
correlated with cell proliferation in meningiomas and malignant brain tumors in vivo.
Virchows Arch 439: 176-184, 2001
8  Colitz CMH, Malarkey DE, Dykstra MJ, McGahan MC, Davidson MG: Histologic and
immunohistochemical characterization of lens capsular plaques in dogs with cataracts.
Am J Vet Res 61: 139-143, 2000
9  Dhaene K, Van Marck E, Parwaresch R: Telomeres, telomerase and cancer: an up-date.
Virchows Arch 437: 1-16, 2000
10  Eagle RC, Font RL, Swercsek TW: Malignant medulloepithelioma of the optic nerve in a
horse. Vet Pathol 15: 488-494, 1978
11  Espinosa de los Monteros A, Fernandez A, Millan MY, Rodriguez F, Herraez P, Martin de
las Mulas J: Coordinate expression of CK7 and 20 in feline and canine carcinomas. Vet
Pathol 36: 179-190, 1999
12  Feng J, Funk WD, Whang S-S, Weinrich SL, Avilion AA, Chiu C-P, Adams RR, Chang E,
Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW, Villeponteau
B: The RNA Component of Human Telomerase. Science 269: 1236-1241, 1995
13  Fu W, Killen M, Pandita TK, Mattson MP: The catalytic subunit of telomerase is expressed
in developing brain neurons and serves a cell survival-promoting function. J Mol
Neurosci 14: 3-15, 2000
14  Funakoshi Y, Nakayama,H., Uetsuka,K., Nishimura,R., Sasaki,N., Doi,K.: Cellular
proliferation and telomerase activity in canine mammary gland tumors. Vet Pathol 37:
177-183, 2000
15  Hendrix DVH, Bochsler PN, Saladina B, Cawrse MA, Thomas J: Malignant teratoid
medulloepithelioma in a llama. Vet Pathol 37: 680-683, 2000
16  Ickowski KA, Pantazis CG, McGregor DH, Wu Y, Tawfik OW: Telomerase reverse
transcriptase subunit immunoreactivity. A marker for high-grade prostate carcinoma.
Cancer 95: 2487-2493, 2002
17  Jelinek F, Mirejovsky P, Voskova D, Hron P: Medulloepithelioma in a cat. Cesko-slovenska
patologie 32: 75-77, 1996
18  Khoddami M, Becker LE: Immunohistochemistry of medulloepithelioma and neural tube.
Pediatric Pathology & Laboratory Medicine 17: 913-925, 1997
19  Kim NW, Piatyszek MA, Prowse PR, Harley CB, West MD, Ho PLC, Coviello GM, Wright
WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with
immortal cells and cancer. Science 266: 2011-2014, 1994
20  Kivela T, Tarkkanen A: Recurrent medulloepithelioma of the ciliary body. Ophthalmology
95: 1565-1575, 1988
21  Kyo S, Masutomi K, Maida Y, Kanaya T, Tanaka M, Takarada M, Sugawara I, Murakami S,
Taira T, Inoue M: Significance of immunological detection of human telomerase reverse
transcriptase. Am J Pathol 163: 859-867, 2003
22  LaBowit SE, Katz,H.R., Hirschbein,M.J., Oswald,M.R., Snyder,L.S., Schwartz,K.S.,
Herling,I.E.: Topical 0.3% ciprofloxacin vs topical 0.3% ofloxacin in early treatment of
pseudomonas aeruginosa keratitis in a rabbit model. Ann Ophthalmol 33: 48-52, 2001
23  Lahav M, Albert DM: Medulloepithelioma of the ciliary body in the goldfish(Carassius
auratus). Vet Pathol 15: 208-212, 1978
24  Lahav M, Albert DM, Kircher CH, Percy DH: Malignant teratoid medulloepithelioma in a
dog. Vet Pathol 13: 11-16, 1976
25  Langloss JM, Zimmerman LE, Krehbiel JD: Malignant intraocular teratoid
medulloepithelioma in three dogs. Veterinary Pathology 13: 343-352, 1976
26  Laver NM, Hidayat AA, Croxatto JO: Pleomorphic adenomas of the ciliary epithelium:
Immunohistochemical and ultrastructural features of 12 cases. Ophthalmology 106: 103,
1999
27  Mattson MP, Fu W, Zhang P: Telomerase, DNA Damage and Apoptosis. In: Telomerase,
Aging and Disease, eds. Mattson MPPandita TK, pp. 131-150. Elsevier Science,
Amsterdam, 2001
28  Mattson MP, Klapper,W.: Emerging roles for telomerase in neuronal development and
apoptosis. Journal of Neuroscience Research 63: 1-9, 2001
29  Moll R, Lowe A, Laufer J, Franke WW: CK20 in human carcinomas. A new histodiagnostic
marker detected by monoclonal antibodies. Am J Pathol 140: 427-447, 1992
30  Moll R, Schiller DL, Franke WW: Identification of protein IT of the intestinal cytoskeleton
as a novel type I CKwith unusual properties and expression patterns. J Cell Biol 111:
567-580, 1990
31  Nakayama J-i, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide
T, Ishikawa F: Telomerase activation by hTRT in human normal fibroblasts and
hepatocellular carcinomas. Nature Genetics 18: 65-68, 1998
32  Poremba C, Heine B, Diallo R, Heinecke A, Wai D, Schaefer KL, Braun Y, Schuck A,
Lanvers C, Bankfalvi A, Kneif S, Torhorst J, Zuber M, Kochli OR, Mross F, Dieterich H,
Sauter G, Stein H, Fogt F, Boecker W: Telomerase as a prognostic marker in breast
cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 198:
181-189, 2002
33  Poremba C, Scheel,C., Hero,B., Christiansen,H., Schaefer,K.L., Nakayama,J.I., Berthold,F.,
Juergens,H., Boecker,W., Dockhorn-Dworniczak,B.: Telomerase activity and telomerase
subunits gene expression patterns in neuroblastoma: a molecular and
immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-
embedded tissues. Journal of Clinical Oncology 18: 2582-2592, 2000
34  Ramaekers F, Huysmans A, Schaart G, Moesker O, Vooijs P: Tissue distribution of keratin 7
as monitored by a monoclonal antibody. Exp Cell Res 170: 235-249, 1987
35  Ramaekers F, van Niekerk C, Poels L, Schaafsma E, Huijsmans A, Robben H, Schaart G,
Vooijs P: Use of monoclonal antibodies to keratin 7 in the differential diagnosis of
adenocarcinomas. Am J Pathol 136: 641-655, 1999
36  Rhyu MS: Telomeres, Telomerase and Immortality. J Natl Cancer Inst 87: 884-894, 1995
37  Schmidt RE, Becker LL, McElroy JM: Malignant teratoid medulloepithelioma in two
cockatiels. J Am Vet Med Assoc 189: 1105-1106, 1976
38  Schneider-Stock R, Boltze C, Jager V, Epplen J, Landt O, Peters B, Rys J, Roessner A:
Elevated telomerase activity, c-MYC, and hTERT mRNA expression: association with
tumour progression in malignant lipomatous tumors. J Pathol 199: 517-525, 2003
39  Tahara H, Yasui W, Tahara E, al e: Immuno-histochemical detection of human telomerase
catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections.
Oncogene 18: 1561-1567, 1999
40  Terasaki H, Nagasaka T, Arai M, Harada T, Miyake Y: Adenocarcinoma of the
nonpigmented ciliary epithelium: report of two cases with immunohistochemical
findings. Graefes Arch Clin Exp Ophthalmol 239: 876-881, 2001
41  Tseng SCG, Jarvinen MJ, Nelson WG, Huang JW, Woodcock-Mitchell J, sun TTI:
Correlation of specific keratins with different types of epithelial differentiation:
Monoclonal antibody studies. Cell 30: 361, 1982
42  Ueda Y, Senba H, Nishimura T, Usui T, Tanaka K, Inagaki S: Ocular medulloepithelioma in
a thoroughbred. Equine Veterinary Journal 25: 558-561, 1993
43  Wang Z, Ramin SA, Tsai C, Lui P, Ruckle HC, Beltz RE, Sands JF, Slattery CW: Evaluation
of PCR-ELISA for determination of telomerase activity in prostate needle biopsy and
prostatic fluid specimens. Urologic Oncology 7: 199-205, 2002
44  Weinrich SL, Pruzan,R., Ma,L., Ouellette,M., Tesmer,V.M., Holt,S.E., Bodnar,A.G.,
Lichsteiner,S., Kim,N.W., Trager,J.B., Taylor,R.D., Carlos,R., Andrews,W.H.,
Wright,W.E., Shay,J.W., Harley,C.B., Morin,G.B.: Reconstitution of human telomerase
with the template RNA component hTR and the catalytic protein subunit hTRT. Nature
Genetics 17: 498-502, 1997
45  Wilcock B, Williams MM: Malignant intraocular medulloepithelioma in a dog. Journal of the
American Animal Hospital Association 16: 617-619, 1980
46  Yanoff M, Fine BS: Ocular Melanocytic Tumors. In: Ocular Pathology, 5 ed., pp. 639-699.
Mosby, Philadelphia, 2002




Slide ID Signalment Diagnosis
Adenoma (Non-Inv)
1 01RD287 FS, 9 yr, Lab Ret non-pigmented, iridociliary adenoma
2 01RD325 FE, 6 yr, Greyhound non-pigmented, iridociliary adenoma
3 01RD597 FE, 7 yr, Lab Ret partially pigmented, iridociliary adenoma
4 01RD829 FS, 7 yr, Lab Ret non-pigmented, iridociliary adenoma
5 00RD895 MN, 9 yr, Mix Breed partially pigmented, iridociliary adenoma
6 00RD978 MN, 10 yr, Lab Ret non-pigmented, iridociliary adenoma
7 01RD1158 MN, 7 yr, ShepherdX non-pigmented, iridociliary adenoma
Adenoma (Invasive)
8 01RD084 MN, 5.2 yr, Aust Cattle Dg iridociliary adenoma
9 94RD104 12 yr, Brittany Spaniel non-pigmented, ciliary body tumor
10 98RD142 FE, 8 yr, Shih Tzu non-pigmented, ciliary body adenoma
11 01RD324 FS, 6 yr, Cocker/Terrier non-pigmented, iridociliary adenoma
12 00RD586 FS, 6 yr, Boston Terrier non-pigmented, iridociliary adenoma
13 99RD648 FS, 1 yr, German Shp partially pigmented, iridociliary adenoma
14 00RD1100 FS, 11 yr, Yorkshire Ter non-pigmented, iridociliary adenoma
Adenocarcinomas
15 01RD089 MN, 8 yr, Lab Ret iridociliary adenocarcinoma
16 00RD0305 MN, 10 yr, Golden Ret iridociliary adenocarcinoma
17 00RD0394 MN, 5 yr, Schnauzer iridociliary adenocarcinoma
18 00RD0510 MN, 12 yr, Mix Breed iridociliary adenocarcinoma
19 00RD1209 13 yr, ShepherdX iridociliary adenocarcinoma
20 00RD1277 FS, 6 yr, ShepherdX iridociliary adenocarcinoma
21 00RD1279 MN, 9 yr, Poodle adenocarcinoma
Medulloepithelioma
22 92RD060 ML, 6 yr, Lab Ret medulloepithelioma
23 97RD114 FE, 1 yr, Malamute medulloepithelioma
24 02RD332 unknown medulloepithelioma
25 96RD537 FE, 10 mo, Beagle retinoblastoma/medulloepithelioma
26 97RD614 FS, 4 yr, Lab Ret ocular medulloepithelioma
27 00RD1057 MN, 12 yr, Cocker Spaniel teratoid medulla epithelioma
Table 2:
Slide ID Antibodies
Adenoma (Non-Invasive) TERT (1:350) CK #20 CK #7 AE1:AE3
1 01RD287 0 0 0 1
2 01RD325 0 2 0 0
3 01RD597 1 2 0 1
4 01RD829 0 2 0 0
5 00RD895 1 2 0 1
6 00RD978 0 2 0 1
7 01RD1158 1 0 0 1
Adenoma (Invasive)
8 01RD084 1 2 0 0
9 94RD104 0 0 0 1
10 98RD142 2 0 0 1
11 01RD324 2 2 0 1
12 00RD586 2 0 0 0
13 99RD648 2 0 0 1
14 00RD1100 2 0 0 0
Adenocarcinomas
15 01RD089 2 0 0 2
16 00RD0305 2 0 0 2
17 00RD0394 2 0 0 0
18 00RD0510 2 0 0 2
19 00RD1209 2 0 0 2
20 00RD1277 2 0 0 2
21 00RD1279 2 0 0 1
Medulloepithelioma
22 92RD060 2 0 0 0
23 97RD114 2 0 0 0
24 02RD332 1 0 0 0
25 96RD537 2 0 0 0
26 97RD614 1 0 0 2
27 00RD1057 2 0 0 0
Table 3:
Tumor Type TERT CK 20 CK 7 AE1/AE3
Adenoma (Non-
Invasive)
0.4286 2.000 0.000 1.429
Adenoma (Invasive) 1.833 0.5714 0.000 1.143
Adenocarcinoma 2.000 0.000 0.000 1.571
Medulloepithelioma 2.000 0.000 0.000 0.000
Data presented is the mean of the immunostaining rating.
Figures:
Figure 1:  Non-invasive adenoma immunostained for (A) telomerase, (B) for CK20 (CK 20),
(C) AE 1/AE 3, and (D) CK7 (CK 7). Chromogen is NovaRed for telomerase antibody and DAB
for CK20, CK7, and AE1/AE3, all are counterstained with hematoxylin, magnification is 40X.
Figure 2:  Invasive adenoma immunohistochemically stained for (A) telomerase, (B) CK20 (CK
20),  (C) AE 1/AE 3, and (D) CK7 (CK 7). Chromogen is NovaRed for telomerase antibody and
DAB for CK20, CK7, and AE1/AE3, all are counterstained with hematoxylin, magnification is
40X.
Figure 3:  Adenocarcinoma immunohistochemically stained for (A) telomerase, (B) CK20 (CK
20),  (C) AE 1/AE 3, and (D) CK7 (CK 7). Chromogen is NovaRed for telomerase antibody and
DAB for CK20, CK7, and AE1/AE3, all are counterstained with hematoxylin, magnification is
40X.
Figure 4:  Medulloepithelioma immunohistochemically stained for (A) telomerase, (B) AE 1/AE
3, and (C) AE 1/AE 3 and (D) CK7 (CK 7). Chromogen is NovaRed for telomerase antibody and
DAB for CK20, CK7, and AE1/AE3, all are counterstained with hematoxylin, magnification is
40X.
Figure 5: Bar graphs of immunohistochemical staining score averages for tumors stained with
(A) TERT, (B) CK20, and (C) AE1/AE3.
